Angelo Schenone - Concepedia

Author

Angelo Schenone

Also Known As

A SCHENONE, A Schenone, A. Schenone, Alessandro Picelli, Andrew Schaefer, Angelo E. Schenone, Angelo Schenone, Erica Biassoni, F. Camozzi, Gian Mancardi

383

Publications

10.4K

Citations

H-Index

199

Concepts

All Affiliations

University of Genoa Ospedale Policlinico San Martino Fondazione IRCCS Istituto Neurologico Carlo Besta Istituti di Ricovero e Cura a Carattere Scientifico University of Verona

About

Angelo Schenone is an author at University of Genoa specializing in medicine, neurology, and neuropathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	86	5.3K
2	Health Sciences	15	18	1.3K
3	Engineering	3	3	49
4	Arts	1	1	20
5	Language Studies	1	1	20

Angelo Schenone

165

Publications

8.2K

Citations

H-Index

Page 1

	Year	Citations
Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2 Alessandra Bolino, M. Muglia, F. L. Conforti, Nature Genetics Myotubularin-related Protein-2Mendelian DisorderGenetic DisorderGeneticsPathogenesis	2000	457
Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network Axel Niemann, Marcel Rüegg, Veronica La Padula, The Journal of Cell Biology MitophagyGeneticsCell DeathGanglioside-induced DifferentiationMitochondrial Network	2005	391
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings Guido Cavaletti, David R. Cornblath, Ingemar S. J. Merkies, Annals of Oncology Health SciencesPeripheral Nerve InjuryPain MedicineReliability FindingsDiabetic Neuropathy	2012	284
Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial Davide Pareyson, Mary M. Reilly, Angelo Schenone, The Lancet Neurology MedicineAscorbic AcidDental DiseasePathology	2011	260
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial Ivo N. van Schaik, Vera Bril, Nan van Geloven, The Lancet Neurology Subcutaneous ImmunoglobulinAutoimmune DiseaseChronic InflammatoryMaintenance TreatmentImmunotherapy	2017	258
Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial Eduardo Nobile‐Orazio, Dario Cocito, S. Jann, The Lancet Neurology Autoimmune DiseaseSclerodermaChronic InflammatoryMedicineImmunology	2012	213
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3 Lorenzo Maggi, Luca Bello, Silvia Bonanno, Journal of Neurology Neurosurgery & Psychiatry	2020	186
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin Paola Alberti, Emanuela Rossi, David R. Cornblath, Annals of Oncology NeurotoxicologyPharmacologyNeuropathic PainPatient-reported Outcome MeasuresSame Coin	2013	171
Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP Andrea Cortese, Raffaella Lombardi, Chiara Briani, Neurology Neuroimmunology & Neuroinflammation	2019	170
Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database Pietro Emiliano Doneddu, Dario Cocito, Fiore Manganelli, Journal of Neurology Neurosurgery & Psychiatry	2018	144

Page 1